Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

PHASE2TerminatedINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

February 25, 2015

Primary Completion Date

February 6, 2017

Study Completion Date

February 6, 2017

Conditions
Huntington's Disease
Interventions
DRUG

20 mg BID of PF-02545920

All subject who completed A8241021 will receive 20 mg BID (with or without titration)

Trial Locations (50)

10117

Charité - Universitätsmedizin Berlin, Berlin

12208

Albany Medical College, Albany

23562

Universität zu Lübeck, Lübeck

27157

Wake Forest Baptist Medical Center, Winston-Salem

31505

Krakowska Akademia Neurologii Sp. zo.o, Krakow

32607

University of Florida Center for Movement Disorders & Neurorestoration, Gainesville

35043

Philipps Universitat Marburg, Marburg

35233

The Kirkland Clinic of UAB Hospital, Birmingham

University of Alabama at Birmingham, Birmingham

43221

The Ohio State University, Columbus

The Wexner Medical Center at the Ohio State University, Columbus

The Wright Center of Innovation- The Ohio State University, Columbus

44791

St. Josef Hospital, Bochum

46202

Indiana University Health Neuroscience Center, Indianapolis

48149

George-Huntington-Institut, Münster

52074

Uniklinik RWTH Aachen, Aachen

63110

Washington University School of Medicine, St Louis

77030

Baylor College of Medicine, Houston

80113

Rocky Mountain Movement Disorders Center, Englewood

80462

Copernicus Podmiot Leczniczy sp.zo.o, Gdansk

81675

Technische Universität München, München

84416

Kbo-Isar-Amper-Klinikum gGmbH, Taufkirchen

85259

Mayo Clinic Arizona, Scottsdale

89081

Universitätsklinikum Ulm, Ulm

90095

Ronald Reagan UCLA Medical Center Drug Information Center, Los Angeles

UCLA Neurology Clinic, Los Angeles

UCLA Radiology, Los Angeles

91054

Friedrich-Alexander-Universität, Erlangen

92697

University of California, Irvine, Irvine

97080

Universitaetsklinikum Wuerzburg, Würzburg

V6T 2B5

The Centre For Huntington Disease, The University of British Columbia, Vancouver

M3B 2S7

Center For Movement Disorders, Toronto

H2L 4M1

CHUM-Notre-Dame Hospital, Montreal

H4L 4M1

CHUM-Notre-Dame, Pharmacie, Montreal

60-529

Solumed Centrum Medyczne, Poznan

02957

Instytut Psychiatrii i Neurologii, I Klinika Neurologiczna, Warsaw

M13 9WL

Central Manchester University Hospitals NHS Foundation Trust, Oxford Road

The National Institute for Health Research / Wellcome Trust Clinical Research Facility, Manchester

NE3 3XT

St Nicholas Hospital, Gosforth

B15 2FG

Bimingham & Solihull Mental Health NHS Foundation Trust Department of Neuropsychiatry, Birmingham

AB25 2ZA

NHS Grampian, Aberdeen Royal Infirmary, Clinical Genetics Centre, Aberdeen

CF14 4XW

Institute of Psychological Medicine and Clinical Neurosciences, Cardiff

G51 4TF

NHS Greater Glasgow and Clyde, Glasgow

SE19RT

Guy's and St. Thomas' NHS Foundation Trust, London

wc1b 5eh

University College London Hospitals Huntington's Diesease, London

WC1N 3BG

University College London Hospitals NHS Foundation Trust, London

NE4 5PL

Newcastle Magnetic Resonance Centre, Newcastle upon Tyne

OX3 9DU

Oxford University Hospitals NHS Trust, Oxford

S10 2JF

Sheffield Teaching Hospital NHS Foundation Trust, Sheffield

SO16 6YD

University Hospital Southampton NHS Foundation Trust, Wessex Neurological Centre, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02342548 - Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021 | Biotech Hunter | Biotech Hunter